Canntab Therapeutics Limited
CTABF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -44.4% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | -$0 | $0 | $0 |
| % Margin | -320.1% | – | 100% | 59.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3 | $3 | $2 | $2 |
| SG&A Expenses | $3 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $3 |
| Operating Income | -$4 | -$4 | -$3 | -$3 |
| % Margin | -1,419.4% | – | -1,961.8% | -1,042.4% |
| Other Income/Exp. Net | $0 | -$1 | $0 | $0 |
| Pre-Tax Income | -$4 | -$4 | -$3 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$4 | -$3 | -$2 |
| % Margin | -1,257.6% | – | -1,955.4% | -1,024.4% |
| EPS | -0.098 | -0.13 | -0.096 | -0.097 |
| % Growth | 24.8% | -35.4% | 1.2% | – |
| EPS Diluted | -0.098 | -0.13 | -0.096 | -0.097 |
| Weighted Avg Shares Out | 38 | 35 | 27 | 25 |
| Weighted Avg Shares Out Dil | 38 | 35 | 27 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$2 | -$3 | -$2 | -$2 |
| % Margin | -848% | – | -1,713.8% | -1,008.8% |